OBIO

Orchestra BioMed Holdings, Inc.

Healthcare
Biotechnology
$367M market cap

Forecast run · Sep 14, 2026Upside rank 1174 of 3,136

Model Signal

ForecastQ Daily Probabilities

41.7%

74.1%

29.3%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$6.12

Price target$11.00

Implied move+79.7%

Analysts6

ForecastQ Portfolios

OBIO is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.